Another inconvenient truth: Combining the risks from obesity and metabolic syndrome with global warming

Current Atherosclerosis Reports

Volumn 10, Issue 4, 2008, Pages 273-276

  Clearfield, Michael ^a  

^a Touro University California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN;

ABDOMINAL OBESITY; AIR QUALITY; CARDIOVASCULAR RISK; CLIMATE CHANGE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; GREENHOUSE EFFECT; HEALTH STATISTICS; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORTALITY; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL ACTIVITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

AIR POLLUTION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS; GLOBAL WARMING; HUMANS; HYPERCHOLESTEROLEMIA; METABOLIC SYNDROME X; OBESITY; PREVALENCE; UNITED STATES;

EID: 58649084985     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0041-z     Document Type: Review

References (35)

1. Centers for Disease Control and Prevention: Life expectancy. Available at http://www.cdc.gov/NCHS/pressroom/07newsrelease/lifeexpectancy.htm. Accessed on January 28, 2008.
2. American Heart Association: Heart Disease and Stroke Statistical-2004 Update. Available at http://www.americanheart.com/ presenter.jhtml?identifier=3018163. Accessed on January 28, 2008.
3. Neftel A, Moor E, Oeschger H, et al.: Evidence from polar ice cores for the increases in atmospheric CO2 in the past two centuries. Nature 1985, 315: 45-47.
4. Thoning KW, Tans PP, Komhyr WD, et al.: Atmospheric carbon dioxide at Mauna Loa Observatory 2. Analysis of the NOAA GMCC data. 1974-1985. J Geophys Res 1989, 94: 8549-8565.
5. Ford ES, Ajani UA, Croft JB, et al.: Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356: 2388-2398.
6. U.S. Census Bureau: Sixty-Five Plus in The United States. Available at http://www.census.gov/population/socdemo/statbriefs/agebrief.html. Accessed on January 28, 2008.
7. Bibbins-Domingo, Coxson P, Pletcher MJ, et al.: Adolescent overweight and future adult coronary heart disease. N Engl J Med 2007, 357: 2371-2379.
8. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes and obesity related health risk factors, 2001. JAMA 2003, 289: 76-79.
9. Reaven GM: Importance of identifying the overweight patient who will benefit the most from losing weight. Ann Intern Med 2003, 138: 420-423.
10. Despres JP, LemiNux I, Prudhomme D: Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001, 322: 716-720.
11. Girman CJ, Rhodes T, Mercuri M, et al.: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study and the Air Force/Texas Coronary Atheroscelerosis Prevention Study. Am J Cardiol 2004, 93: 136-141.
12. Clearfield M, Downs JR, Lee M, et al.: Implications from the Air Force/ Texas Coronary Atherosclerosis Study for the Adult Treatment Panel III Guidelines. Am J Cardiol 2005, 96: 1674-1680.
13. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and the Treatment of High Blood Cholesterol in Adults. Circulation 2002, 106: 3143-3373.
14. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk. Circulation 2004, 109: 2818-2825.
15. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107: 499-511.
16. Clearfield M: Statins and the primary prevention of cardiovascular events. Curr Atheroscler Reports 2006, 8: 390-396.
17. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 325: 20-28.
18. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL-C, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352: 29-38.
19. Nissen SE, Nicholls SJ, Siphai I, et al.: Effect of very high intensity statin therapy of regression of coronary atherosclerosis. JAMA 2006, 295: 1556-1565.
20. O'Keefe JH, Cordain L, Harris WH, et al.: Optimal LDL is 50 to 70 mg/ dl. J Am Coll Cardiol 2004, 43: 2142-2146.
21. Leeper NJ, Ardehali R, deGoma EM, et al.: Statin use in patients with extremely low LDL levels is associated with improved survival. Circulation 2007, 116: 613-618.
22. Brown MS, Goldstein JL: Lowering LDL-not only how low, but how long? Science 2006, 311: 1721-1723
23. Baker JL, Olsen LW, Sorensen T: Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007, 357: 2329-2337.
24. Rodenburg J, Vissers MN, Wiegman A, et al.: Statin treatment in children with familial hypercholesterolemia-the younger the better. Circulation 2007, 116: 664-668.
25. National Research Council: Research Priorities for Airborne Particulate Matter, I: Immediate Priorities and Long Range Research Portfolio. Washington, DC: National Academy Press; 1998.
26. Laden F, Schwatz J, Speizer FE, et al.: Reduction in fine particulate air pollution and mortality. Extended follow-up of the Harvard Six Cities study. Am J Resp Crit Care Med 2006, 173: 667-672.
27. Pope CA, Burnett RT, Thun MJ, et al.: Lung cancer, cardiopulmonary mortality and long term exposure to fine particulate air pollution. JAMA 2002, 287: 1132-1141.
28. McCreanor J, Cullinan P, Nieuwenhuijsen MJ, et al.: Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med 2007, 357: 2348-2358.
29. Down SH, Schindler C, Liu S, et al.: Reduced exposure to PM10 and attenuated age related decline in lung function. N Engl J Med 2007, 357: 2338-2347.
30. Patz JA, Kovats RS: Hotspots in climate change and human health. BMJ 2002, 325: 1094-1098.
31. World Health Organization: WHO Issues New Healthy Life Expectancy Rankings. Available at http://www.who.int/infpr-2000/en/ pr2000-life.html. Accessed on January 29, 2008.
32. World Health Organization: World Health Statistics 2005. Available at http://www3.who.int.statistics. Accessed on January 29, 2008.
33. World Resources Institute: U.S. Ranks Second to Last in Global Climate Rankings; European Countries Dominate Top Ten. Available at http://earthtrends.wri.org/updates/node/267. Accessed on January 29, 2008.
34. Ridker PM, Fonseca AH, Genest J, et al.: Baseline characteristics of participants in the JUPITER trial: A randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007, 100: 1659-1664.
35. JUPITER closes early due to unequivocal evidence of benefit. Available at: http://www.theheart.org/article/852735.do. Accessed April 27, 2008.